Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Phase 3 N=49 Randomized Treatment

Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic ACL Surgery

ACL Injury · Postoperative Pain

Bottom Line

View on ClinicalTrials.gov: NCT04246554 ↗
Enrolled (actual)
49
Serious AEs
0.0%
Results posted
Dec 2021
Primary outcome: Primary: Postoperative Visual Analogue Scale Scores — 50.4; 40.0 score on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Ketorolac (Drug); Oxycodone-Acetaminophen (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University Hospitals Cleveland Medical Center
Primary completion
Oct 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Postoperative Visual Analogue Scale Scores		 50.4; 40.0 —
SECONDARY
Narcotic Medication		 12.4; 5.5 —

Summary

1. The investigators aim to examine the use of IV and oral ketorolac as an adjunctive agent to the standard of care pain protocol for postoperative pain control following ACL reconstruction surgery. 2. The investigators hypothesize that the use of IV and oral ketorolac in addition to the standard of care pain protocol will reduce postoperative opioid consumption following ACL reconstruction surgery.

Eligibility Criteria

Inclusion Criteria

  • Patients between 18 and 89 years old
  • Patients undergoing primary anterior cruciate ligament (ACL) reconstruction surgery

Exclusion Criteria

  • Patients below age 18 or above age 89
  • Illiterate or non-English speaking individuals
  • Patients with contraindications to Ketorolac
  • History of chronic alcohol or drug abuse
  • Chronic use of psychotropic or analgesic drugs
  • Known peptic ulcer disease or bleeding diasthesis
  • Renal dysfunction (estimated glomerular filtration rate < 50 mL/min/1.73m2)
  • Breastfeeding women
  • Pregnant women
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04246554). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search